MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock
- None.
- None.
The automatic conversion of MiMedx Group's Preferred Stock into Common Stock is a noteworthy event that simplifies the company's capital structure and can potentially affect investor sentiment. By eliminating the dividend obligations associated with the Preferred Stock, the company is likely to experience an immediate reduction in cash outflows, improving liquidity. However, the addition of approximately 30 million shares of Common Stock increases the number of outstanding shares, which could lead to earnings dilution if the company does not proportionately increase its net income.
Investors should monitor the company's future earnings reports to assess the impact of this dilution on earnings per share (EPS). Additionally, the conversion being triggered by an increase in common share price is indicative of positive market reception to the company's performance and may reflect investor confidence in its growth trajectory.
The conversion event suggests that MiMedx Group is in a transition phase, aiming to streamline its financial structure and focus on growth. The mention of significant commercial momentum and disciplined expense controls in 2023 indicates a strategic shift towards operational efficiency. This could be appealing to investors who prioritize companies with lean operations and clear paths to profitability.
Furthermore, the ongoing support from EW Healthcare Partners and Hayfin Capital Management underscores the confidence of institutional investors in MiMedx's potential. This kind of endorsement can be a positive signal to the market, potentially attracting further investment and driving up the stock's demand.
The conversion of Preferred Stock to Common Stock in a biotech firm like MiMedx Group often reflects underlying strategic initiatives aimed at improving financial agility. For stakeholders, this move could be indicative of the company's readiness to invest more aggressively in research and development or pursue market expansion. The company's ability to innovate and grow within the competitive biotech landscape will be critical for its long-term success.
Given that the conversion was part of a planned financial restructuring following a financing transaction, it reflects a premeditated approach to capital management. Stakeholders should evaluate upcoming product pipelines and market penetration strategies to understand how this restructuring might support the company's core business objectives.
MARIETTA, Ga., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that its outstanding 95,000 shares of Series B Convertible Preferred Stock (the “Preferred Stock”), together with any accrued dividends, were automatically converted into shares of the Company’s Common Stock on December 22, 2023, in accordance with the Preferred Stock terms set forth in the Company’s Articles of Incorporation. As a result of this conversion, approximately 30 million shares of Common Stock have been added to the Company’s share count. The conversion of the shares ends the dividend accrual associated with the Preferred Stock.
Commenting on the conversion, MIMEDX Chief Executive Officer, Joseph H. Capper stated, “Today marks an important milestone in our journey to improve MIMEDX’s financial profile. The Preferred Stock conversion, triggered by the Company’s increased Common Stock share price and following the third anniversary of the Preferred Stock financing transaction in July of 2020, simplifies our balance sheet and eliminates an ongoing dividend payment obligation.”
Mr. Capper continued, “By infusing much-needed financial support during a critical phase in the Company’s evolution, EW Healthcare Partners and Hayfin Capital Management provided MIMEDX with the resources necessary to reshape the Company and position it for growth well into the future. As a result, we are now starting to generate momentum and believe our most exciting times are still ahead of us, as we continue to grow and innovate. We are eternally grateful to these two exceptional partners and for the support they have provided MIMEDX.”
Martin P. Sutter, co-founder and managing director of EW Healthcare Partners, stated, “We are delighted with the progress MIMEDX has made since our initial investment, and particularly over the course of 2023, which has been marked by significant commercial momentum and disciplined expense controls. EW Healthcare Partners looks forward to continuing its long-term support as MIMEDX seeks to cement its leadership position in the industry.”
About MIMEDX
MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit www.mimedx.com.
Forward Looking Statements
This press release may contain statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the future operating performance of MIMEDX and MIMEDX’s pursuit of growth and innovation. Additional forward looking statements may be identified by words such as "believe," "expect," "may," "plan," “goal,” “outlook,” "potential," "will," "preliminary," and similar expressions, and are based on management's current beliefs and expectations. Investors are cautioned that any such forward looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward looking statements as a result of various factors. Important factors that could cause such differences are described in MIMEDX’s periodic filings with the Securities and Exchange Commission. Any forward looking statements speak only as of the date of this press release and MIMEDX assumes no obligation to update any forward looking statement.
Contact:
Matt Notarianni
Investor Relations
470-304-7291
mnotarianni@mimedx.com
FAQ
What did MiMedx Group, Inc. (MDXG) announce?
What are the implications of the conversion?
Who provided financial support to MiMedx Group, Inc. (MDXG)?
What did the CEO express gratitude for?
